Read about the latest updates happening at the EDDU

The Neuro’s EDDU is proud to share that Carol Chen, Research Assistant at the Early Drug Discovery Unit, has been awarded the 2023 Champion Award for Research Staff, alongside Claire Magnussen, Nikhil Bhagwat, and Samir Das. This award is a part of The Neuro Open Science Internal Awards, supported by Tanenbaum Open Science Institute to recognize researchers, staff, graduate and undergraduate students at The Neuro who have shown leadership and creativity in Open Science, inspiring peers and fostering a community of Open Science practice. Congratulations to all the awardees on this well deserved recognition of your work and commitment to Open Science!

The Neuro’s EDDU is proud to share that Thomas

Durcan, the Director of the EDDU, is co-principal

investigator of the new testing platform TRIDENT. In

a partnership between McGill University and

Western University, TRIDENT strives to identify

promising therapeutics against neurodegenerative

diseases such as Alzheimer’s and Parkinson’s earlier,

redirecting efforts and funding to the most promising

therapeutics. The New Frontiers in Research Fund’s

transformation stream has granted TRIDENT $24

million over six years.

Through advanced testing models, and a unique

focus on cognition, the platform will help bring drugs

with the most therapeutic potential to market and

assist researchers to assess whether these drugs

deliver the health outcomes anticipated.

To learn more, go to: https://healthenews.mcgill.ca/mcgill-partners-with-western-university-to-revolutionize-drug-development-for-brain-diseases-with-24m-federal-funding-boost/

Image of an iPSC-derived gut organoid

by Faiza Benaliouad

Read the EDDU's monthly newsletter to learn more about the latest events and achievements happening at the EDDU!

Click here to read the May 2023 newsletter.

The Neuro’s EDDU is proud to be part of the Neuro-CERVO Alliance for Drug Discovery in Brain Diseases (NCADD) initiative. NCADD’s vision is to embrace patients’ heterogeneity to develop effective treatment to neurological conditions such as Parkinson’s disease, schizophrenia and bipolar disorder. Through a unique unbiased scientific approach, combining deep patients’ characterization and artificial intelligence, our mission is to address major challenges in the neuroscience field such as finding biomarkers for neurological disorders, enabling drug target discovery, and facilitating the development of personalized therapies. NCADD’s core objective is to be a catalyst for public-private collaborations and for growth of the life science sector in Quebec.

To learn more, go to: https://www.neuro-cervo.org/

We are happy to announce our next virtual iPSC workshop which will take place on June 21st and 22nd. This is an excellent opportunity to learn about working with human induced pluripotent stem cells (hiPSCs) and how they can be differentiated into neuronal cell types.

The application deadline is June 2nd.